Assertio/ASRT

$0.93

-2.83%
-
1D1W1MYTD1YMAX

About Assertio

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Ticker

ASRT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brendan O'Grady

Employees

53

Headquarters

Lake forest, United States

Assertio Metrics

BasicAdvanced
$95M
Market cap
-
P/E ratio
-$3.95
EPS
0.93
Beta
-
Dividend rate
$95M
0.92657
$6.57
$0.73
1M
1.866
1.448
28.716
28.716
-95.65%
-172.9%
-130.77%
0.67
0.707
3.304
2.844
-12.4%
-366.05%
12.69%

What the Analysts think about Assertio

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 3 analysts.
213.98% upside
High $3.00
Low $2.75
$0.93
Current price
$2.92
Average price target

Assertio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-13.88% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$32M
-1.52%
Net income
-$4.5M
-92.15%
Profit margin
-13.88%
-92.03%

Assertio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 66.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.13
-$3.42
-$0.61
-$0.05
-
Expected
$0.14
$0.07
-$0.02
-$0.03
-$0.04
Surprise
-9.88%
-4,706.06%
2,950%
66.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Assertio stock?

Assertio (ASRT) has a market cap of $95M as of May 30, 2024.

What is the P/E ratio for Assertio stock?

The price to earnings (P/E) ratio for Assertio (ASRT) stock is 0 as of May 30, 2024.

Does Assertio stock pay dividends?

No, Assertio (ASRT) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Assertio dividend payment date?

Assertio (ASRT) stock does not pay dividends to its shareholders.

What is the beta indicator for Assertio?

Assertio (ASRT) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Assertio stock price target?

The target price for Assertio (ASRT) stock is $2.92, which is 213.98% above the current price of $0.93. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Assertio stock

Buy or sell Assertio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing